Scinovex
article Open Access

The effects of antifibrinolytic drug use in decreasing hemoglobin drop following Percutaneous Nephrolithotomy in Al-Hillah Province

International Journal of Surgery Science · 2023 · Vol. 7(1) · pp. 32–37
Adel Ibraheem Al-NajjarAbdulridha Mohammed Ali ShubbarDheyaa Ali Hussein

Abstract

Introduction: Objective: To assess the effectiveness and safety of tranexamic acid in lowering postoperative haemoglobin and hematocrit decline, operational time, postoperative complications, and hospitalisation in percutaneous nephrolithotomy patients. Methods: A 40-patient Al-Hilla Teaching Hospital randomised controlled clinical trial ran from January 2020 through July 2022. All ultrasound-guided PCNL patients with renal stones were randomised into two groups. Group A consisted of 20 patients (13 males and 7 females) with a mean age of (45.05 ±12.23) years who received tranexamic acid (1gm slow intravenous infusion diluted in 100 cc normal saline over 10 minutes) on call to surgery and then (0.5 gm infusion every 8 hours for the first 24 hours postoperatively). Group B included 20 non-tranexamic acid-treated patients (9 males and 11 females) with a mean age of 42.15 ± 10.64 years. We are comparing haemoglobin and hematocrit decline, operational time, postoperative complications, and hospitalisation between two groups. Results: Group A had a much lower postoperative haemoglobin decline than group B, 12.97 ±1.21 g/dl vs 11.82 ±1.44 (p = 0.010). Group A had a much lower postoperative hematocrit decline (39.11 ±3.95%) than group B (34.86 ±3.73%) (p = 0.001). 63.25 ±10.79 minutes against 73.50 ±16.31 minutes (p = 0.024). Group A had a significantly shorter hospital stay than group B (54.00 ±10.66 hours vs. 60.60 ±11.74 hours, p = 0.021). All patients in two groups had postoperative moderate hematuria, however group B had 4 (20.0%) instances of severe hematuria, whereas group A had just one (5%) case (p = 0.047). Four (20.0%) group B patients and one (5%) group A case required blood transfusion, a statistically significant difference (p = 0.047). Conclusions: TXA reduces postoperative haemoglobin and hematocrit drops and blood transfusions in PCNL with minimal side effects and a shorter operational time and hospital stay.

Kidney Stones and Urolithiasis TreatmentsDialysis and Renal Disease ManagementRenal function and acid-base balanceMedicineTranexamic acidHematocritPercutaneous nephrolithotomyAnesthesiaSurgeryGroup BHemoglobinSalinePercutaneous
Citations
1
FWCI
0.26
field-weighted impact
References
22
Percentile
60%
vs. same field & year
References
EAU Guidelines on Interventional Treatment for Urolithiasis
European Urology · 2015 · 1,783 citations
Complications in Percutaneous Nephrolithotomy
European Urology · 2006 · 935 citations
Prevalence of Kidney Stones in the United States
European Urology · 2012 · 2,538 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

The effects of antifibrinolytic drug use in decreasing hemoglobin drop following Percutaneous Nephrolithotomy in Al-Hillah Province · Scinovex